Drug intelligence / Profile preview

A168

Development stage: Phase 1
Lead developer: Kelun-Biotech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Injection

Overview

A168 is a recombinant anti-vascular endothelial growth factor receptor 2 (VEGFR2) fully human monoclonal antibody injection. It is currently undergoing a Phase I clinical study to evaluate its safety, tolerability, and pharmacokinetic characteristics in patients with advanced solid tumors, both as a monotherapy and in combination with paclitaxel for advanced gastric adenocarcinoma or gastroesophageal adenocarcinoma. The drug is being developed by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Other names: ramucirumab biosimilarrecombinant anti-VEGFR2 fully human monoclonal antibodyrecombinant fully human anti-VEGFR2 monoclonal antibody

Targets

VEGFR2 (Vascular endothelial growth factor receptor 2)

Beyond the preview

Go deeper on A168.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on A168.